Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors in cancer of unknown primary site

  • Correspondence
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ponce Lorenzo J, Segura Huerta A, Díaz Beveridge R et al (2007) Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables. Clin Trans Oncol 9:452–458

    Article  CAS  Google Scholar 

  2. Muñoz A, Fuente N, Barceló R et al (2004) Prognostic and predictive factors of patients with cancer of unknown origin treated with a paclitaxel-based chemotherapy. Med Clin (Barc) 122:216–218

    Article  Google Scholar 

  3. Hainsworth JD, Erland JB, Kalman LA et al (1997) Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15:2385–2393

    PubMed  CAS  Google Scholar 

  4. Culine S, Kramar A, Saghatchian M et al (2002) Development of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679–4683

    Article  PubMed  Google Scholar 

  5. Köhne CH, Cunningham D, Di Costanzo F et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13:308–317

    Article  PubMed  Google Scholar 

  6. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  7. Kabbinavar F, Zurlo A, Irl C et al (2006) Bevacizumab improves outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) independent of baseline risk. J Clin Oncol 24[Suppl]:155s, abstr 3539

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hospital de Cruces, Osakidetza-SVS, Plaza de Cruces s/n, 48903, Bizkaia, Basque Country, Spain

    Alberto Muñoz, Natalia Fuente, Itziar Rubio, Josefa Ferreiro, Alejandro Martínez-Bueno & Guillermo López-Vivanco

Authors
  1. Alberto Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalia Fuente
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Itziar Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Josefa Ferreiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alejandro Martínez-Bueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guillermo López-Vivanco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Muñoz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muñoz, A., Fuente, N., Rubio, I. et al. Prognostic factors in cancer of unknown primary site. Clin Transl Oncol 10, 64–65 (2008). https://doi.org/10.1007/s12094-008-0156-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-008-0156-2

Keywords

Search

Navigation